Logo

Lilly Acquires Hydra Biosciences with its Pre-Clinical Pain Program for Chronic Pain Syndromes

Share this

Lilly Acquires Hydra Biosciences with its Pre-Clinical Pain Program for Chronic Pain Syndromes

Shots:
  • Lilly to acquire Hydra- in all stock transaction with its all pre-clinical pain program of TRPA1 antagonists
  • The focus of the acquisition is to develop treatments for chronic pain and understand TRP pathway in pain signaling- further initiate clinical trials
  • Hydra’s Transient Receptor Potential (TRP) channel program consists of group of non-selective cation channels indicated for the treatment of pain- inflammation and hypertension
Ref: Eli Lilly | Image:  PM Live

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions